Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

Published:2008 Issue:3 Volume:47 Page:203-216
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clinical Pharmacokinetics

Author:

Mueck Wolfgang,Eriksson Bengt I,Bauer Kenneth A,Borris Lars,Dahl Ola E,Fisher William D,Gent Michael,Haas Sylvia,Huisman Menno V,Kakkar Ajay K,Kälebo Peter,Kwong Louis M,Misselwitz Frank,Turpie Alexander G G

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. Current Options in the Prevention of Thromboembolic Disease

2. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

3. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

4. Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

5. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study;Frontiers in Pharmacology;2024-09-06

2. Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK);Clinical and Translational Science;2024-06

3. Pharmacodynamic Study of Parallel Groups Comparing the Effect of Rivaroxaban 20 Mg (Laboratorios Leti, S.A.V.) vs Rivaroxaban 20 Mg (Bayer Laboratories) on Prothrombin Time;International Journal of Clinical Medicine;2024

4. Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study;Advances in Therapy;2023-11-21

5. Platelet-rich fibrin ensures hemostasis after single-tooth removal under factor Xa inhibitors — a clinical prospective randomized split-mouth study;Clinical Oral Investigations;2023-10-21